Novartis AG (NVS) is a Drug Manufacturers - General company in the Healthcare sector, currently trading at $153.38. It has a SharesGrow Score of 68/100, indicating a above average investment profile with 4 out of 7 criteria passed.
SharesGrow calculates the intrinsic value of NVS = $297.22 (+93.8% from the current price, the stock appears undervalued). Analyst consensus target is NVS = $127 (-17.2% upside).
Valuation: NVS trades at a trailing Price-to-Earnings (P/E) of 20.9 (S&P 500 average ~25) with a forward Price/Earnings-to-Growth (PEG) of 2.06.
Financials: revenue is $54.8B, +2.3%/yr average growth. Net income is $14.1B, growing at +37.2%/yr. Net profit margin is 25.6% (strong). Gross margin is 75% (+4.9 pp trend).
Balance sheet: total debt is $37.0B against $46.1B equity (Debt-to-Equity (D/E) ratio 0.8, moderate). Current ratio is 1.12 (adequate). Debt-to-assets is 32%. Total assets: $115.6B.
Analyst outlook: 6 / 25 analysts rate NVS as buy (24%) — mixed sentiment.
SharesGrow 7-Criteria breakdown: Value 40/100 (Partial), Growth 73/100 (Pass), Past 100/100 (Pass), Health 67/100 (Partial), Moat 94/100 (Pass), Future 16/100 (Fail), Income 85/100 (Pass).
